NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (“Evome”, the “Company”) (TSXV: EVMT) announced the resignation of Michael Dalsin as Chairman of the Board of Directors. Mr. Chris Heath will remain on the Board and continues to work to capture shareholder value in the various assets held by Evome.
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) is providing an update to shareholders today.
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) announces the appointment of Michael Dalsin as Chairman of the Board of Directors. Kenneth Kashkin, MD will take the role of Vice-Chairman. Bill Garbarini will retain his role as COO while stepping off the Board of Directors. Chris Heath was also appointed as a new Director increasing the size of the Board of Directors from five to six.
SHIRLEY, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) issued a press release on Monday, February 10, 2025 announcing the details of an amendment (the “Amendment”) to the forbearance agreement dated August 4, 2023 between the Company, Biodex Rehab Systems, LLC (“Biodex Rehab”), a wholly owned subsidiary of the Company, and Biodex Medical Systems, Inc. (“Biodex Medical”), a wholly owned subsidiary of Biodex Rehab, and Mirion Technologies (US), Inc. (“Mirion”).
SHIRLEY, N.Y., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) has announced a significant reduction in its overall debt, strengthening its financial position, as a result of the execution of an amendment (the “Amendment”) to the forbearance agreement dated August 4, 2023 between the Company, Biodex Rehab Systems, LLC (“Biodex Rehab”), a wholly owned subsidiary of the Company, and Biodex Medical Systems, Inc. (“Biodex Medical”), a wholly owned subsidiary of Biodex Rehab, and Mirion Technologies (US), Inc. (“Mirion”).
SHIRLEY, N.Y., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) is pleased to announce that the Company's Board of Directors has approved the grant of 1,000,000 restricted stock units (RSUs) to William Garbarini in connection with his appointment as Chief Operating Officer, effective November 22, 2024.
Launches Evome Medical Products Distribution Company, Appoints Bill Garbarini Chief Operating Officer Adding Plan for a broader portfolio of Life Science Products Launches Evome Medical Products Distribution Company, Appoints Bill Garbarini Chief Operating Officer Adding Plan for a broader portfolio of Life Science Products
SHIRLEY, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today announced the results from its annual general and special meeting of shareholders held on November 8, 2024 (the “Meeting”) in Shirley, New York. The total number of shares represented in person or by proxy at the Meeting was 18,991,213, representing 31.2% of the total issued and outstanding voting shares of the Company.
Posts updated corporate presentation to website Reminder: Conference call to be held on August 19 th to discuss Q2 2024 financial results SHIRLEY, N.Y., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) highlights its low-CapEx plan for growing revenue in an updated corporate presentation now available at www.evomemedical.com/investor.
SHIRLEY, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today reported financial results for the second quarter ended June 30, 2024, featuring $421,000 in positive Adjusted EBITDA1, a reduction in debt, financial performance momentum and significant progress with its restructuring. The Company's financial statements for the three and six months ended June 30, 2024 and 2023 and related Management's Discussion and Analysis (MD&A) are available under the Company's profile on SEDAR+ (www.sedarplus.com).
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) is pleased to announce it has entered into an agreement ("Agreement") with IR Labs Inc. ("irlabs") to provide the Company with investor relations and communications services.
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today provided details on preliminary estimated revenues and margins from April and May 2024, the first two months of the second quarter. Mike Seckler, Chief Executive Officer of the Company, will also hold a call to update shareholders on the first quarter financials, second quarter progress and future plans of the Company.
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today reported continued progress on its turn-around plan. Evome has grown revenue at its core business unit, Biodex Medical Systems, Inc. (“Biodex”), while reducing total debt significantly for the third straight quarter.
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) announced today preliminary annual financial results for the year ending December 31, 2023. Because of a strong fourth quarter, the Company generated positive Adjusted EBITDA for 2023.
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “ Company ” or “ Evome ”) (TSXV: EVMT), is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market making services, including use of its proprietary algorithm, ICP Premium™, for its shares traded on the TSX Venture Exchange (the “TSXV”), in compliance with the policies of the TSXV and other applicable legislation. ICP will receive a fee of C$7,500 plus applicable taxes per month, payable monthly in advance. The agreement between the Company and ICP is for an initial term of four (4) months and shall be automatically renewed for subsequent one (1) month terms (each month called an "Additional Term") unless either party provides at least thirty (30) days written notice prior to the end of the initial term or an Additional Term, as applicable. There are no performance fees contained in the agreement and no stock options or other compensation are being granted in connection with the engagement. ICP and its clients may acquire an interest in the securities of the Company in the future.
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) announces the appointment of two senior healthcare executives to its Board of Directors.
NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Salona Global Medical Device Corporation (the “Company”) (TSXV:SGMD), is pleased to announce its corporate name change to Evome Medical Technologies Inc. on January 22, 2024, and trading of the Company's common shares on the TSX Venture Exchange will commence under the ticker symbol "EVMT" on January 22, 2024. The name change reflects the Company's commitment as a high-tech physical therapy medical device company. Appointed in June 2023, Mr. Seckler has successfully implemented strategic imperatives that have resulted in the establishment of the new Evome Medical Technologies Inc:
NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Salona Global Medical Device Corporation (the “Company”) (TSXV:SGMD), announced today it has executed an exclusive distribution agreement with Veteran Medical Solutions, LLC (“VMS”), a U.S. military veteran owned company that is positioned to sell the Company's Biodex branded equipment.
NEW YORK, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Salona Global Medical Device Corporation (the “Company”) (TSXV:SGMD), announced today the debut of the Biodex Reactive Step Trainer (“RST”): A revolutionary medical device that combines Biodex Rehab's industry leading gait trainer platform with a clinically proven perturbation training system.
NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Salona Global Medical Device Corporation (the “Company”) (TSXV:SGMD), soon to be renamed Evome Medical Technologies Inc., today announced the debut of the Biodex SpaceTek Knee™ Device: A revolutionary, portable medical device for treating patients with knee replacements and knee injuries.